[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hemmat et al., 2021 - Google Patents

The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

Hemmat et al., 2021

View HTML
Document ID
4609769824782671361
Author
Hemmat N
Asadzadeh Z
Ahangar N
Alemohammad H
Najafzadeh B
Derakhshani A
Baghbanzadeh A
Baghi H
Javadrashid D
Najafi S
Ar Gouilh M
Baradaran B
Publication year
Publication venue
Archives of Virology

External Links

Snippet

The number of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21 st century. Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages

Similar Documents

Publication Publication Date Title
Hemmat et al. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
Astuti Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
Fung et al. Human coronavirus: host-pathogen interaction
Sa Ribero et al. Interplay between SARS-CoV-2 and the type I interferon response
Tufan et al. COVID-19, immune system response, hyperinflammation and repurposingantirheumatic drugs
Kindler et al. Interaction of SARS and MERS coronaviruses with the antiviral interferon response
Thiel et al. Interferon and cytokine responses to SARS-coronavirus infection
Li et al. SARS‐CoV‐2 infection‐induced immune responses: Friends or foes?
Zarandi et al. SARS-CoV-2: from the pathogenesis to potential anti-viral treatments
Zhang et al. Ubiquitin-modified proteome of SARS-CoV-2-infected host cells reveals insights into virus–host interaction and pathogenesis
Wen et al. Seneca Valley virus 2C and 3C inhibit type I interferon production by inducing the degradation of RIG-I
Zhang et al. ISGylation in innate antiviral immunity and pathogen defense responses: a review
Zhou et al. Cellular RNA helicase DDX1 is involved in transmissible gastroenteritis virus nsp14-induced interferon-beta production
Li et al. Innate immune responses to duck Tembusu virus infection
Raj et al. Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives
Zhao et al. Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication
Manhas et al. Covid-19 pandemic and current medical interventions
Ebrahim-Saraie et al. Functional and structural characterization of SARS-Cov-2 spike protein: an in silico study
Rabaan et al. An updated review on pathogenic coronaviruses (CoVs) amid the emergence of SARS-CoV-2 variants: A look into the repercussions and possible solutions
Masucci Viral ubiquitin and ubiquitin-like deconjugases—Swiss Army knives for infection
Roy Chattopadhyay et al. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters
Singh et al. COVID-19: pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies
Bannazadeh-baghi et al. Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection
Tarigan et al. Modulation of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in receptor, innate immunity and drug antiviral candidate
Hemmat et al. The alterations of cellular signaling pathways in the host cell upon the high pathogenic Coronaviruses infection, SARS-CoV and MERS-CoV. What could be expected from the SARS-CoV-2?